Document is current

Article History

Received: 30 August 2025

Accepted: 29 January 2026

First Online: 16 February 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hospital Universitario La Paz (Madrid, Spain). Protocol Code: PI 2995. Informed consent was obtained from all subjects involved in the study prior to inclusion.

: PA and CT received grants related to this work (see Funding section). PA has received grants and personal fees from Alexion, AbbVie, Amgen, Faes, Gedeon Richter, GP Pharm, Kyowa Kirin, Lilly, Rubió, and Theramex outside the submitted work. CT has received personal fees for participation in scientific presentations for Alexion Pharmaceuticals, Amgen, UCB, Gedeon Richter, Grünenthal, and Theramex, and for participation in the Advisory Board of Alexion, outside the submitted work. VNC reports grants and personal fees from Abbvie, Alfasigma, Janssen, Lilly, Novartis, Pfizer, UCB, Novartis, and Janssen outside the submitted work. SGC reports personal fees from Abbvie, UCB, Gedeon Richter, Amgen, Grünenthal, Rubió, and Theramex, outside the submitted work; IM has received honoraria as a speaker from Roche, Novartis, UCB, Janssen, Galapagos, Biopharma and Gedeon Richter, and for consultancies from UCB and Roche outside the submitted work. CT, VNC, KH, SMH, AB, SGC, IM, and PA declare no other conflicts of interest.